UK Markets closed

Sanofi (SAN.PA)


Paris - Paris Delayed price. Currency in EUR
Add to watchlist
82.67+0.76 (+0.93%)
At close: 5:35PM CEST
People also watch
FP.PABN.PACS.PAOR.PAAI.PA
Full screen
Previous close81.91
Open82.10
Bid71.12 x 1000
Ask71.74 x 44000
Day's range82.10 - 83.75
52-week range66.72 - 92.97
Volume2,398,290
Avg. volume2,417,231
Market cap100.81B
Beta0.74
PE ratio (TTM)11.44
EPS (TTM)N/A
Earnings dateN/A
Dividend & yield3.30 (3.50%)
Ex-dividend date2017-05-16
1y target estN/A
  • Reutersyesterday

    FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)

    Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its follow-on biologic version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.

  • Merck's Biosimilar Insulin Gets Tentative FDA Approval
    Zacks4 days ago

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

  • Reuters4 days ago

    U.S. jury sides with Amphastar over Momenta in drug patent trial

    A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.